REGN: Leadership change

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. 1. New Equity Awards for CEO and CSO Effective September 24, 2026 (the “ Grant Date ”), the Compensation Committee (the “ Compensation Committee ”) of the Board of Directors (the “ Board ”) of Regeneron Pharmaceuticals, Inc. (“ Regeneron ” or the “ Company ”) granted, upon the approval of the independent, non-employee members of the Board, a one-time award of performance share units (together, the “ 2026 PSUs ”) under the Second Amended and Restated Regeneron Pharmaceuticals, Inc. 2014 Long-Term Incentive Plan (the “ Equity Plan ”) to each of Leonard S. Schleifer, M.D., Ph.D., Board co-Chair, President and Chief Executive Officer of the Company (“ CEO ”), and George D. Yancopoulos, M.D., Ph.D., Board co-Chair, President and Chief Scientific Officer of the Company (“ CSO ”), as described below. THE 2026 CEO AND CSO AWARDS OVERVIEW This summary highlights certain features of the 2026 PSUs and is qualified by the supplemental information in Exhibit 99.1 and the 2026 PSU agreements filed as Exhibits 10.1 and 10.2. · Designed to drive long-term, sustainable value creation. The 2026 PSUs reward successful, timely execution by Regeneron’s co-founders Drs. Schleifer and Yancopoulos against ambitious pipeline and commercial growth goals sustained through the full 10-year performance period, which is aligned with Regeneron’s mission, focus on long-term value creation, and product development and commercialization cycles. · Thoughtful, multi-year process that incorporated shareholder input. The award structure is a result of a multi-year process led by the Compensation Committee and directly reflects feedback from many of the